Nasus Pharma files to sell up to $8.5 million in shares via ATM offering

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company, entered into an At-The-Market Sales Agreement with BTIG, LLC on September 18, 2026, covering the potential sale of ordinary shares with an aggregate offering price of up to $8,500,000 through BTIG as sales agent.¹ The company said it is not obligated to sell any shares under the agreement.¹ Nasus shares trade on NYSE American under "NSRX," and the last reported sale price on September 17, 2026 was $3.53 per share.¹

Nasus is developing a powder-based intranasal drug delivery platform, and its lead program is NS002, an intranasal epinephrine candidate, while a second program, NS001, an intranasal naloxone, has been paused as the company looks for partnering opportunities.¹ On NS002, the company disclosed that it had filed an Investigational New Drug application with the FDA in the third quarter of 2026, and that the application remained under agency review at the time of this filing, as stated in the prospectus supplement. The company also noted it opened a further Canadian Phase 2 trial for NS002 in November 2025, structured as an open-label study comparing NS002 to EpiPen in sequence, enrolling 50 healthy adults with a history of allergic rhinitis, evaluating pharmacokinetic parameters and hemodynamic responses,¹ with positive topline results announced in March 2026.¹

Nasus said it plans additional steps ahead: an additional Phase 2 study evaluating self-administration, followed by a pivotal Phase 3 study targeted for the fourth quarter of 2026, before an FDA marketing submission.¹ Proceeds from the ATM offering are intended for ongoing clinical development of NS002 for anaphylaxis treatment, initiation of studies for other pipeline products, and working capital and general corporate purposes.¹ As of June 30, 2026, the company's accumulated deficit stood at $24.5 million,¹ and Nasus said it expects to need substantial additional funding going forward.¹